CorMedix Inc
NASDAQ:CRMD
CorMedix Inc
Goodwill
CorMedix Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CorMedix Inc
NASDAQ:CRMD
|
Goodwill
$30m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Goodwill
$48.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Goodwill
$21.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Goodwill
$71.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Goodwill
$21.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Goodwill
$5.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
CorMedix Inc
Glance View
CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.
See Also
What is CorMedix Inc's Goodwill?
Goodwill
30m
USD
Based on the financial report for Dec 31, 2025, CorMedix Inc's Goodwill amounts to 30m USD.
